转基因小鼠
海马体
神经炎症
内科学
内分泌学
二肽基肽酶
认知功能衰退
化学
药理学
受体
胰高血糖素样肽-1
转基因
陶氏病
医学
神经退行性变
生物化学
糖尿病
2型糖尿病
炎症
疾病
痴呆
酶
基因
作者
Zongyang Li,Yuan Zhang,Xiangbao Meng,Min Li,Weiwei Cao,Junshan Yang,Xudong Xu,Wenlan Liu,Weiping Li,Qian Cai,Sicen Wang,Guoxu Ma,Zhiheng Liu,Guodong Huang
摘要
Abstract Enhancing glucagon‐like peptide 1 (GLP‐1) signaling with a dipeptidyl peptidase IV (DPP‐4) inhibitor might exert protective effects on Alzheimer's disease (AD). We found that intragastric administration of Gramcyclin A (10, 20 and 40 mg/kg), a novel DPP‐4 inhibitor, for 3 months significantly reversed cognitive decline in APP/PS1/tau triple transgenic mice in a dose‐dependent manner. Gramcyclin A treatment markedly reduced Aβ plaques as well as the insoluble and soluble forms of Aβ40 and Aβ42 in the hippocampus of APP/PS1/tau mice. Treatment with Gramcyclin A remarkedly decreased the level of microglia and suppressed neuroinflammation in the hippocampus of APP/PS1/tau mice. Moreover, Gramcyclin A treatment could increase brain glucose uptake in APP/PS1/tau mice, as detected by 18‐fluoro‐2‐deoxyglucose ( 18 F‐FDG) micro‐positron emission tomography (micro‐PET) imaging. Furthermore, Gramcyclin A significantly increased expression of glucagon‐like peptide‐1 (GLP‐1), GLP‐1R, proliferator‐activated receptor gamma coactivator (PGC)‐1α and glucose transporter 4 (GLUT4), and inhibited insulin receptor (IRS)‐1 phosphorylation and tau hyperphosphorylation in the hippocampus of APP/PS1/tau mice. Collectively, Gramcyclin A conferred protective effects against AD via enhancing brain GLP‐1‐dependent glucose uptake. The DPP‐4 inhibitor Gramcyclin A might be a potential therapeutic drug for AD.
科研通智能强力驱动
Strongly Powered by AbleSci AI